- Home
- LYEL vs STXS Comparison
LYEL vs STXS Comparison
Compare LYEL & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- STXS
- Stock Information
- Founded
- LYEL 2018
- STXS 1990
- Country
- LYEL United States
- STXS United States
- Employees
- LYEL N/A
- STXS N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LYEL Health Care
- STXS Health Care
- Exchange
- LYEL Nasdaq
- STXS Nasdaq
- Market Cap
- LYEL 253.2M
- STXS 275.9M
- IPO Year
- LYEL 2021
- STXS 2004
- Fundamental
- Price
- LYEL $17.75
- STXS $2.67
- Analyst Decision
- LYEL Hold
- STXS Strong Buy
- Analyst Count
- LYEL 3
- STXS 1
- Target Price
- LYEL $16.67
- STXS $4.00
- AVG Volume (30 Days)
- LYEL 27.0K
- STXS 445.9K
- Earning Date
- LYEL 11-12-2025
- STXS 11-11-2025
- Dividend Yield
- LYEL N/A
- STXS N/A
- EPS Growth
- LYEL N/A
- STXS N/A
- EPS
- LYEL N/A
- STXS N/A
- Revenue
- LYEL $60,000.00
- STXS $31,806,000.00
- Revenue This Year
- LYEL N/A
- STXS $30.98
- Revenue Next Year
- LYEL N/A
- STXS $49.86
- P/E Ratio
- LYEL N/A
- STXS N/A
- Revenue Growth
- LYEL 11.11
- STXS 33.94
- 52 Week Low
- LYEL $7.65
- STXS $1.54
- 52 Week High
- LYEL $30.00
- STXS $3.59
- Technical
- Relative Strength Index (RSI)
- LYEL 59.71
- STXS 36.19
- Support Level
- LYEL $15.77
- STXS $2.68
- Resistance Level
- LYEL $17.75
- STXS $3.15
- Average True Range (ATR)
- LYEL 1.15
- STXS 0.12
- MACD
- LYEL -0.18
- STXS -0.05
- Stochastic Oscillator
- LYEL 69.86
- STXS 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.